Depletion of B220+NK1.1+ cells enhances the rejection of established melanoma by tumor-specific CD4+ T cells.

abstract：:Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC). IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigate...

journal_title：Oncoimmunology

authors： Ferretti E,Di Carlo E,Ognio E,Guarnotta C,Bertoni F,Corcione A,Prigione I,Fraternali-Orcioni G,Ribatti D,Ravetti JL,Ponzoni M,Tripodo C,Pistoia V

更新日期：2015-06-19 00:00:00

abstract：:The persistence of leukemic stem cells (LSCs) in acute myeloid leukemia (AML) patients receiving chemotherapy may be responsible for the high frequency of relapse. The selective elimination of CD96+ AML-LSCs by means of CD96-specific monoclonal antibodies may be a promising therapeutic approach and revitalize autologo...

journal_title：Oncoimmunology

authors： Staudinger M,Humpe A,Gramatzki M

更新日期：2013-06-01 00:00:00

abstract：:We have previously reported a novel phenotype of myeloid suppressors in lymphoma patients characterized by a loss of HLA-DR expression on monocytes, CD14+HLA-DRlow/neg. These cells were directly immunosuppressive and were associated with poor clinical outcome. In this study, we found that lymphoma tumors could have mo...

journal_title：Oncoimmunology

authors： Zhang ZJ,Bulur PA,Dogan A,Gastineau DA,Dietz AB,Lin Y

更新日期：2015-01-26 00:00:00

abstract：:T lymphocytes can mediate the destruction of cancer cells by virtue of their ability to recognize tumor-derived antigenic peptides that are presented on the cell surface in complex with HLA molecules and expand. Thus, the presence of clonally expanded T cells within neoplastic lesions is an indication of ongoing HLA-r...

journal_title：Oncoimmunology

authors： Sittig SP,Køllgaard T,Grønbæk K,Idorn M,Hennenlotter J,Stenzl A,Gouttefangeas C,Thor Straten P

更新日期：2013-09-01 00:00:00

abstract：:The loss-of-function mutation of formyl peptide receptor 1 (FPR1) has a negative impact on the progression-free and overall survival of breast cancer patients treated with anthracycline-based adjuvant chemotherapy. This effect may be attributed to the fact that chemotherapy-induced antitumor immunity requires FPR1 and...

journal_title：Oncoimmunology

authors： Baracco EE,Pietrocola F,Buqué A,Bloy N,Senovilla L,Zitvogel L,Vacchelli E,Kroemer G

更新日期：2016-02-18 00:00:00

abstract：:Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-infiltrating lymphocytes has shown to positively correlate with patient...

journal_title：Oncoimmunology

authors： Maas RJ,Hoogstad-van Evert JS,Van der Meer JM,Mekers V,Rezaeifard S,Korman AJ,de Jonge PK,Cany J,Woestenenk R,Schaap NP,Massuger LF,Jansen JH,Hobo W,Dolstra H

更新日期：2020-11-08 00:00:00

abstract：:Although the profile of safety of tumor-targeted oncolytic virus (TOV) is encouraging, the antitumor efficacy of TOV alone is disappointing. Interleukin-10 (IL-10) plays an important role in carcinogenesis and anti-virus immunity. Here we report that tumor-targeted oncolytic vaccinia virus (VV) armed with IL10 shows p...

journal_title：Oncoimmunology

authors： Chard LS,Lemoine NR,Wang Y

更新日期：2015-07-20 00:00:00

abstract：:Vaccines designed to abrogate the tolerance of tumor self-antigens and amplify cytotoxic CD8+ T cells (CTLs) have promise for the treatment of cancer. Type I natural killer (NKT) cells have attracted considerable interest in the cancer therapy field. In the current study, we have exploited the unique ability of NKT ce...

journal_title：Oncoimmunology

authors： Ghinnagow R,De Meester J,Cruz LJ,Aspord C,Corgnac S,Macho-Fernandez E,Soulard D,Fontaine J,Chaperot L,Charles J,Soncin F,Mami-Chouaib F,Plumas J,Faveeuw C,Trottein F

更新日期：2017-08-18 00:00:00

abstract：:Galectin-9 has emerged as a promising biological target for cancer immunotherapy due to its role as a regulator of macrophage and T-cell differentiation. In addition, its expression in tumor cells modulates tumor cell adhesion, metastasis, and apoptosis. Malignant mesothelioma (MM) is an aggressive neoplasm of the mes...

journal_title：Oncoimmunology

authors： Bertino P,Premeaux TA,Fujita T,Haun BK,Marciel MP,Hoffmann FW,Garcia A,Yiang H,Pastorino S,Carbone M,Niki T,Berestecky J,Hoffmann PR,Ndhlovu LC

更新日期：2019-04-17 00:00:00

abstract：:Mycosis fungoides (MF) progresses from patch to tumor stage by expansion of malignant T-cells that fail to be controlled by protective immune mechanisms. In this study, we focused on IL-32, a cytokine, highly expressed in MF lesions. Depending on the other cytokines (IL-4, GM-CSF) present during in vitro culture of he...

journal_title：Oncoimmunology

authors： Ohmatsu H,Humme D,Gonzalez J,Gulati N,Möbs M,Sterry W,Krueger JG

更新日期：2016-05-05 00:00:00

abstract：:The inspection of the mechanisms through which autophagy modulates immunogenic cell death revealed that the autophagic response of cancer cells to reactive oxygen species-dependent endoplasmic reticulum stress suppresses the exposure of calreticulin on the cell surface, the phenotypic maturation of dendritic cells (DC...

journal_title：Oncoimmunology

authors： Garg AD,Dudek AM,Agostinis P

更新日期：2013-10-01 00:00:00

abstract：:Toll-like receptor 9 (TLR9) is a cellular DNA-receptor of the innate immune system that is widely expressed in cancers. We demonstrated that low tumor TLR9 expression predicts poor disease-specific survival in triple negative breast cancer (TNBC) and renal cell carcinoma (RCC). We hypothesized that this is because TLR...

journal_title：Oncoimmunology

authors： Mella M,Kauppila JH,Karihtala P,Lehenkari P,Jukkola-Vuorinen A,Soini Y,Auvinen P,Vaarala MH,Ronkainen H,Kauppila S,Haapasaari KM,Vuopala KS,Selander KS

更新日期：2015-05-22 00:00:00

abstract：:The versatility and plasticity of myeloid cell polarization/differentiation has turned out to be crucial in health and disease, and has become the subject of intense investigation during the last years. On one hand, myeloid cells provide a critical contribution to tissue homeostasis and repair. On the other hand, myel...

journal_title：Oncoimmunology

authors： Schouppe E,De Baetselier P,Van Ginderachter JA,Sarukhan A

更新日期：2012-10-01 00:00:00

abstract：:Objective:Ovarian cancer (OC) is often diagnosed at an advanced stage with two thirds of patients experiencing recurrent disease with a poor prognosis. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has shown curative potential in malignant melanoma, but has only been investigated scarcely in ot...

journal_title：Oncoimmunology

authors： Pedersen M,Westergaard MCW,Milne K,Nielsen M,Borch TH,Poulsen LG,Hendel HW,Kennedy M,Briggs G,Ledoux S,Nøttrup TJ,Andersen P,Hasselager T,Met Ö,Nelson BH,Donia M,Svane IM

更新日期：2018-09-26 00:00:00

abstract：:Acute infection is known to induce strong anti-tumor immune responses, but clinical translation has been hindered by the lack of an effective strategy to safely and consistently provoke a therapeutic response. These limitations are overcome with a novel treatment approach involving repeated subcutaneous delivery of a ...

journal_title：Oncoimmunology

authors： Bazett M,Costa AM,Bosiljcic M,Anderson RM,Alexander MP,Wong SWY,Dhanji S,Chen JM,Pankovich J,Lam S,Sutcliffe S,Gunn H,Kalyan S,Mullins DW

更新日期：2017-11-27 00:00:00

abstract：:Removal of immuno-suppression has been reported to enhance antitumor immunity primed by checkpoint inhibitors. Although PD-1 blockade failed to control tumor growth in a transgenic murine neuroblastoma model, concurrent inhibition of colony stimulating factor 1 receptor (CSF-1R) by BLZ945 reprogrammed suppressive myel...

journal_title：Oncoimmunology

authors： Eissler N,Mao Y,Brodin D,Reuterswärd P,Andersson Svahn H,Johnsen JI,Kiessling R,Kogner P

更新日期：2016-09-09 00:00:00

abstract：:There is increased production of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) of multiple myeloma (MM) patients and these favor Th22 cell differentiation. Here, we found that the frequency of interleukin (IL)-22+IL-17-IL-13+ T cells is significantly increased in peripheral blood (PB) and BM of stage III...

journal_title：Oncoimmunology

authors： Di Lullo G,Marcatti M,Heltai S,Brunetto E,Tresoldi C,Bondanza A,Bonini C,Ponzoni M,Tonon G,Ciceri F,Bordignon C,Protti MP

更新日期：2015-02-03 00:00:00

abstract：:Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunothera...

journal_title：Oncoimmunology

authors： Kierkels GJ,Straetemans T,de Witte MA,Kuball J

更新日期：2015-08-27 00:00:00

abstract：:Interleukin (IL)-10 is a major cancer-related immunosuppressive factor, exhibiting a unique ability to hamper the maturation of dendritic cells (DCs). We have previously reported that IL-10 induces the conversion of activated, migratory CD1a+ DCs found in the human skin to CD14+CD141+ macrophage-like cells. Here, as a...

journal_title：Oncoimmunology

authors： Lindenberg JJ,van de Ven R,Lougheed SM,Zomer A,Santegoets SJ,Griffioen AW,Hooijberg E,van den Eertwegh AJ,Thijssen VL,Scheper RJ,Oosterhoff D,de Gruijl TD

更新日期：2013-04-01 00:00:00

abstract：:The efficacy of antitumoral responses can be increased using combinatorial vaccine strategies. We recently showed that vaccination could be optimized by local administration of diverse molecular or bacterial agents to target and augment antitumoral CD8 T cells in the genital mucosa (GM) and increase regression of cerv...

journal_title：Oncoimmunology

authors： Domingos-Pereira S,Hojeij R,Reggi E,Derré L,Chevalier MF,Romero P,Jichlinski P,Nardelli-Haefliger D

更新日期：2015-05-22 00:00:00

abstract：:Monoclonal antibodies (mAb) induce tumor regression through antibody-dependant cellular cytotoxicity (ADCC). We recently showed that an agonistic anti-CD137 mAb stimulates natural killer (NK) cells which have been activated by a tumor-specific mAb, resulting in increased ADCC against cancer cells. ...

journal_title：Oncoimmunology

authors： Houot R,Kohrt H,Levy R

更新日期：2012-09-01 00:00:00

abstract：:The elicitation of efficient antitumor immune responses requires the optimal activation of tumor-associated dendritic cells (DCs). Our comparison of the effect of various immunostimulatory treatments on DCs revealed that the best predictor of the success of immunotherapy is not the activation of existing DC population...

journal_title：Oncoimmunology

authors： Kuhn S,Ronchese F

更新日期：2013-11-01 00:00:00

abstract：:Targeting antigens directly to dendritic cells (DCs) in situ has emerged as a promising strategy to potentiate immunity. A recent clinical trial of antibody-mediated targeting of tumor antigen NY-ESO1 to the DC receptor DEC-205 demonstrated an induction of strong cellular and humoral responses. Recent studies with DC-...

journal_title：Oncoimmunology

authors： Dhodapkar MV,Dhodapkar KM

更新日期：2014-08-03 00:00:00

abstract：:Both genetic and environmental factors are thought to be causal in gliomagenesis. Several genes have been implicated in glioma development, but the putative role of a major immunity-related gene complex member, immunoglobulin heavy chain γ (IGHG) has not been evaluated. Prior observations that IGHG-encoded γ marker (G...

journal_title：Oncoimmunology

authors： Pandey JP,Kaur N,Costa S,Amorim J,Nabico R,Linhares P,Vaz R,Viana-Pereira M,Reis RM

更新日期：2014-05-23 00:00:00

abstract：:Purpose: DNA demethylating agents have shown clinical effectiveness in hematological and solid tumors. This trial tested the safety, efficacy, and treatment outcomes of decitabine-based chemotherapy or combined with immunotherapy in recurrent ovarian cancer patients. Patients and methods: Fifty-five patients with recu...

journal_title：Oncoimmunology

authors： Zhang Y,Mei Q,Liu Y,Li X,Brock MV,Chen M,Dong L,Shi L,Wang Y,Guo M,Nie J,Han W

更新日期：2017-05-17 00:00:00

abstract：:The programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) pathway has emerged as a critical inhibitory pathway regulating T-cell response in non-small-cell lung cancer (NSCLC), and the development of PD-1/PD-L1 inhibitors has changed the landscape of NSCLC therapy. Nevertheless, the high degree of non-responders demons...

journal_title：Oncoimmunology

authors： Raimondi C,Carpino G,Nicolazzo C,Gradilone A,Gianni W,Gelibter A,Gaudio E,Cortesi E,Gazzaniga P

更新日期：2017-04-20 00:00:00

abstract：:The prognosis of high-risk neuroblastoma (NB) remains poor, although immunotherapies with anti-GD2 antibodies have been reported to provide some benefit. Immunotherapies can be associated with an IFNγ storm that induces in tumor cells the "adaptive immune resistance" characterized by the de-novo expression of Programm...

journal_title：Oncoimmunology

authors： Dondero A,Pastorino F,Della Chiesa M,Corrias MV,Morandi F,Pistoia V,Olive D,Bellora F,Locatelli F,Castellano A,Moretta L,Moretta A,Bottino C,Castriconi R

更新日期：2015-07-15 00:00:00

abstract：:MDR1 is an ATP-dependent transmembrane transporter primarily studied for its role in the detoxification of tissues and for its implication in resistance of tumor cells to chemotherapy treatment. Several studies also report on its expression on immune cells where it plays a protective role from xenobiotics and toxins. ...

journal_title：Oncoimmunology

authors： Bossennec M,Di Roio A,Caux C,Ménétrier-Caux C

更新日期：2018-09-06 00:00:00

abstract：:We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence of therapy. There is a growing appreciation of the impact of antitumor immune responses to these therapies, ...

journal_title：Oncoimmunology

authors： Cooper ZA,Reuben A,Spencer CN,Prieto PA,Austin-Breneman JL,Jiang H,Haymaker C,Gopalakrishnan V,Tetzlaff MT,Frederick DT,Sullivan RJ,Amaria RN,Patel SP,Hwu P,Woodman SE,Glitza IC,Diab A,Vence LM,Rodriguez-Canales J,P

更新日期：2016-02-02 00:00:00

abstract：:We previously showed that the colorectal cancer colonizing bacterium Fusobacterium nucleatum protects tumors from immune cell attack via binding of the fusbacterial Fap2 outer-membrane protein to TIGIT, a checkpoint inhibitory receptor expressed on T cells and NK cells. Helicobacter pylori, the causative agent for pep...

journal_title：Oncoimmunology

authors： Gur C,Maalouf N,Gerhard M,Singer BB,Emgård J,Temper V,Neuman T,Mandelboim O,Bachrach G

更新日期：2019-01-29 00:00:00